Outcomes following neoadjuvant immunotherapy for oral cavity cancer: A propensity score matched analysis of the National Cancer Database
Poster, American Head and Neck Society Annual Meeting at COSM, New Orleans, LA, USA
This poster discussed how neoadjuvant immunotherapy (NI) for oral cavity squamous cell carcinoma (OCSCC) is a promising approach, but its impact on surgical outcomes and survival has not been well studied. From over 31,000 patients, 1% receieved NI. We found that patients receiving NI had similar postoperative outcomes 30-day mortality, unplanned 30-day readmission, hospital length of stay, surgical margin status, and time to adjuvant radiation. However, NI was associated with improved overall survival, as shown by both Kaplan-Meier and Cox proportional hazard analyses. These findings suggest NI may enhance survival without worsening postoperative outcomes for OCSCC patients, pending validation through future clinical trial results.
Recommended citation: Habib DRS, Shou M, Naranjo C, Adegboye FO, Philips R, Tassone P, Langerman A, Khan A, Topf MC. Outcomes following neoadjuvant immunotherapy for oral cavity cancer: A propensity score matched analysis of the National Cancer Database. Poster presented at: American Head and Neck Society Annual Meeting at COSM; May 15, 2025; New Orleans, LA, USA.
